1
Clinical Trials associated with H2N3 MO 2003/AA ca Vaccine(NIAID)Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic
In recent years, influenza viruses that have traditionally infected animals have infected humans as well. The H2N3 influenza virus, which first appeared in pigs in the Midwest United States in 2006, may pose a potential health concern to humans. This study will evaluate the safety of and immune response to a vaccine designed to protect people from the H2N3 influenza virus.
100 Clinical Results associated with H2N3 MO 2003/AA ca Vaccine(NIAID)
100 Translational Medicine associated with H2N3 MO 2003/AA ca Vaccine(NIAID)
100 Patents (Medical) associated with H2N3 MO 2003/AA ca Vaccine(NIAID)
100 Deals associated with H2N3 MO 2003/AA ca Vaccine(NIAID)